| Jun 13 |
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
|
| Jun 5 |
INAB: INB-200 Update at ASCO24
|
| Jun 3 |
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
|
| May 24 |
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
|
| May 23 |
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
|
| May 20 |
INAB: 1Q:24 Results
|
